Allos Pharma Inc. Receives FDA Guidance for the Design of a Phase 3 Trial to Support a New Drug Application for Treatment of Fragile X Syndrome
CAMBRIDGE, Mass., May 23, 2023 /PRNewswire/ — Allos Pharma Inc. (“Allos”), a biopharmaceutical company specializing in the development of treatments for rare neurological disorders, announced today that it has held a meeting with the U.S. Food and Drug Administration (FDA) to optimize the design of their Phase 3 trial. This trial is designed to support … Read more